Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 1
Terminated
- Conditions
- Pancreatic Neoplasms
- Interventions
- Drug: BI 2536, intravenousDrug: Gemcitabine, intravenous
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02215044
Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 44370 BS
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02215772
The Use of Angiotensin Receptor Blockers and the Risk of Cancer
Completed
- Conditions
- Neoplasm
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1165781
- Registration Number
- NCT02215733
Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT02211859
Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and Their Combination in Constipation and Bloatedness
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02211976
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT02211833
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes
Phase 1
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PlaceboDrug: BI 14332 CL
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 38
- Registration Number
- NCT02212925
Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 14332 CLOther: high fat breakfast
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02212938
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02211963
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 14332 CLDrug: Placebo
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02211989